JP2023515708A5 - - Google Patents
Info
- Publication number
- JP2023515708A5 JP2023515708A5 JP2022565546A JP2022565546A JP2023515708A5 JP 2023515708 A5 JP2023515708 A5 JP 2023515708A5 JP 2022565546 A JP2022565546 A JP 2022565546A JP 2022565546 A JP2022565546 A JP 2022565546A JP 2023515708 A5 JP2023515708 A5 JP 2023515708A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- binder
- optionally
- exogenous
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015936P | 2020-04-27 | 2020-04-27 | |
| US63/015,936 | 2020-04-27 | ||
| PCT/US2021/029455 WO2021222295A1 (en) | 2020-04-27 | 2021-04-27 | Binding agents and uses thereof for central nervous system delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515708A JP2023515708A (ja) | 2023-04-13 |
| JP2023515708A5 true JP2023515708A5 (enExample) | 2024-05-13 |
Family
ID=78332191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565546A Pending JP2023515708A (ja) | 2020-04-27 | 2021-04-27 | 中枢神経系送達のための結合剤及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230173094A1 (enExample) |
| EP (1) | EP4142737A4 (enExample) |
| JP (1) | JP2023515708A (enExample) |
| CN (1) | CN115996760A (enExample) |
| AU (1) | AU2021264512A1 (enExample) |
| CA (1) | CA3176495A1 (enExample) |
| WO (1) | WO2021222295A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| CN116694562B (zh) * | 2023-08-03 | 2023-11-03 | 四川大学华西医院 | 一种BMEC释放的sEV、其制备方法、用途及药物 |
| WO2025054143A2 (en) * | 2023-09-04 | 2025-03-13 | Mercury Bio, Inc. | Protein sorting motifs for the packaging of therapeutic proteins into yeast extracellular vesicles for targeted delivery to cells and blood |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US8877714B2 (en) * | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| CN102482286B (zh) * | 2009-07-02 | 2015-07-15 | 赛诺菲 | 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途 |
| US20110065645A1 (en) * | 2009-09-10 | 2011-03-17 | The Regents Of The University Of California | Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance |
| JP2015535523A (ja) * | 2012-11-12 | 2015-12-14 | アンジオケム インコーポレーテッド | アプロチニン由来ポリペプチド−抗体コンジュゲート |
| GB201220474D0 (en) * | 2012-11-14 | 2012-12-26 | Sagetis Biotech Sl | Polypeptides |
| WO2016172598A1 (en) * | 2015-04-22 | 2016-10-27 | The Broad Institute Inc. | Exosomes and uses thereof |
| BR112019000220A2 (pt) * | 2016-07-06 | 2019-04-24 | National Research Council Of Canada | anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos |
-
2021
- 2021-04-27 WO PCT/US2021/029455 patent/WO2021222295A1/en not_active Ceased
- 2021-04-27 JP JP2022565546A patent/JP2023515708A/ja active Pending
- 2021-04-27 US US17/997,346 patent/US20230173094A1/en active Pending
- 2021-04-27 AU AU2021264512A patent/AU2021264512A1/en active Pending
- 2021-04-27 CA CA3176495A patent/CA3176495A1/en active Pending
- 2021-04-27 CN CN202180047292.2A patent/CN115996760A/zh active Pending
- 2021-04-27 EP EP21795591.3A patent/EP4142737A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515708A5 (enExample) | ||
| JP2022513299A5 (enExample) | ||
| US9387260B2 (en) | VHH antibodies used as peptide vectors for delivering a substance of interest | |
| US11987609B2 (en) | Proteinaceous heterodimer and use thereof | |
| US20150359907A1 (en) | Functionalized DNA Dendrimers For Gene Delivery To Cells | |
| CN116848128A (zh) | 具有非炎症性细胞吞噬作用诱导活性的融合分子 | |
| JP2016027801A (ja) | 改良された抗血清アルブミン結合変異体 | |
| JP2026021333A (ja) | 核酸の自己組織化媒介ａｄｃ薬の構築方法および適用 | |
| CA3255594A1 (en) | EPO RECEPTOR AGONISTS AND ANTAGONISTS | |
| CN116917491A (zh) | 抗体递送 | |
| US20220227827A1 (en) | Proteinaceous heterodimer and use thereof | |
| KR102470059B1 (ko) | 큰 핵산의 표적화된 세포내 전달 | |
| CN115335411B (zh) | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 | |
| JP2023500359A5 (enExample) | ||
| JP2025540336A (ja) | 抗タウ抗体及びペプチドを含む融合体とその用途 | |
| US20250352660A1 (en) | Blood-nerve barrier targeting conjugates and methods of use | |
| US10925968B2 (en) | Cell internalizing compounds | |
| US20250304709A1 (en) | Multispecific binding molecules and methods of use thereof | |
| CA3276286A1 (en) | Fusion comprising anti-tau antibody and peptide and use thereof | |
| CN121319203A (zh) | 双特异性抗体和免疫偶联物及其用途 | |
| WO2025168041A1 (zh) | 治疗2型炎症性疾病的组合物和方法 | |
| WO2023142109A1 (zh) | 一种长效重组人生长激素及其应用 | |
| WO2024089258A1 (en) | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response | |
| CN120399079A (zh) | 靶向cd90的纳米抗体及其应用 | |
| CN121449750A (zh) | 一种双特异性抗体及其应用 |